Management of biochemical recurrence after primary curative treatment for prostate cancer: a review
W Artibani, AB Porcaro, V De Marco, MA Cerruto… - Urologia …, 2018 - karger.com
How to manage patients with prostate cancer (PCa) with biochemical recurrence (BCR)
following primary curative treatment is a controversial issue. Importantly, this prostate …
following primary curative treatment is a controversial issue. Importantly, this prostate …
Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy
PURPOSE: A persistently elevated or rising serum level of prostate-specific antigen (PSA)
after radical prostatectomy is indicative of recurrent prostate cancer. The natural history of …
after radical prostatectomy is indicative of recurrent prostate cancer. The natural history of …
EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer
P Cornford, J Bellmunt, M Bolla, E Briers, M De Santis… - European urology, 2017 - Elsevier
Objective To present a summary of the 2016 version of the European Association of Urology
(EAU)–European Society for Radiotherapy & Oncology (ESTRO)–International Society of …
(EAU)–European Society for Radiotherapy & Oncology (ESTRO)–International Society of …
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer …
Purpose To update eligibility and outcome measures in trials that evaluate systemic
treatment for patients with progressive prostate cancer and castrate levels of testosterone …
treatment for patients with progressive prostate cancer and castrate levels of testosterone …
Development and validation of a dynamic prognostic tool for prostate cancer recurrence using repeated measures of posttreatment PSA: a joint modeling approach
C Proust-Lima, JMG Taylor - Biostatistics, 2009 - academic.oup.com
Prostate-specific antigen (PSA) is a biomarker routinely and repeatedly measured on
prostate cancer patients treated by radiation therapy (RT). It was shown recently that its …
prostate cancer patients treated by radiation therapy (RT). It was shown recently that its …
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy
Purpose: In solid tumors such as prostate cancer, novel paradigms are needed to assess
therapeutic efficacy. We utilized a method estimating tumor growth and regression rate …
therapeutic efficacy. We utilized a method estimating tumor growth and regression rate …
Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy
MC Schumacher, FC Burkhard, GN Thalmann… - European urology, 2008 - Elsevier
BACKGROUND: Conflicting results exist regarding the value of an extended pelvic lymph
node dissection (PLND) in node-positive patients undergoing radical retropubic …
node dissection (PLND) in node-positive patients undergoing radical retropubic …
2-[18F]Fluoro-2-Deoxyglucose Positron Emission Tomography for the Detection of Disease in Patients with Prostate-Specific Antigen Relapse after Radical …
Abstract Experimental Design: Retrospective cohort study in 91 patients with prostate-
specific antigen (PSA) relapse following prostatectomy, imaged with 2-[18F] fluoro-2 …
specific antigen (PSA) relapse following prostatectomy, imaged with 2-[18F] fluoro-2 …
Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer
Purpose: Sipuleucel-T, an autologous cellular immunotherapy, was investigated in a
randomized, double-blind, controlled trial to determine its biologic activity in androgen …
randomized, double-blind, controlled trial to determine its biologic activity in androgen …
Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy
Abstract BACKGROUND. The University of California, San Francisco (UCSF) Cancer of the
Prostate Risk Assessment (CAPRA) is a novel preoperative index which predicts the risk of …
Prostate Risk Assessment (CAPRA) is a novel preoperative index which predicts the risk of …